Bioventus Inc.

Listed Company

BVSCIK 0001665988NasdaqEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$568.09M

Net Income

$22.73M

Total Assets

$683.56M

Equity

$184.10M

Shares Out

Op. Cash Flow

$74.67M

Business

Bioventus Inc. is a global medical device company that relieves pain and addresses musculoskeletal conditions with clinically proven therapies. It offers hyaluronic acid injections and peripheral nerve stimulation devices for pain, ultrasonic surgical systems and bone graft substitutes for surgery, and low‑intensity pulsed ultrasound for bone healing. The company reports results in U.S. and International segments covering Pain Treatments, Surgical Solutions and Restorative Therapies. Bioventus markets products in the United States and internationally through direct sales, distributors and indirect channels to physicians, ambulatory surgical centers and hospitals.

Summary from filing dated 2025-03-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	568	573	512	512	431
Cost of sales (including depreciation and amortization of $41,251, $41,882 and $48,503, respectively)	180	185	184	181	128
Gross profit	388	388	328	331	303
Selling, general and administrative expense	314	344	304	332	254
Research and development expense	12	14	13	24	19
Restructuring costs	2	−52,000	840,000	7	2
Change in fair value of contingent consideration	0	1	719,000	1	829,000
Depreciation and amortization	6	8	9	10	8
Impairment of assets	0	36	79	0	0
Loss on disposals	81,000	292,000	4	0	0
Operating income (loss)	54	−15	−82	−167	12
Interest expense, net	26	39	41	12	1
Loss on extinguishment	326,000	0	0	—	—
Other expense (income)	1	−2	−1	10	1
Other expense	28	37	39	22	3
Income (loss) before income taxes	26	−52	−121	−189	9
Income tax (benefit) expense, net	−2	−5	85,000	−44	−2
Net income (loss) from continuing operations	27	−47	−121	−145	11
Loss from discontinued operations, net of tax	0	0	−74	−69	−2
Net income (loss)	27	−47	−196	−213	10
(Income) loss attributable to noncontrolling interest - continuing operations	−5	11	24	41	10
Loss attributable to noncontrolling interest - discontinued operations	0	0	15	14	0
Net income (loss) attributable to Bioventus Inc.	23	−36	−156	−159	19
Change in prior service cost and unrecognized gain (loss) for defined benefit plan adjustment	21,000	13,000	−8,000	133,000	60,000
Change in foreign currency translation adjustments	2	−4	1	−501,000	−1
Change in the fair value of cash flow hedges	−991,000	0	0	—	—
Comprehensive income (loss)	28	−51	−194	−214	8
Comprehensive (income) loss attributable to noncontrolling interest - continuing operations	−5	12	24	41	10
Comprehensive loss attributable to noncontrolling interest - discontinued operations	0	0	15	14	0
Comprehensive income (loss) attributable to Bioventus Inc.	23	−39	−155	−159	18
Continuing operations, basic (in dollars per share)	0.34	−0.56	−1.54	−1.7	−0.11
Discontinued operations, basic (in dollars per share)	0	0	−0.95	−0.89	−0.04
Basic income (loss) per Class A common stock (in dollars per share)	0.34	−0.56	−2.49	−2.59	−0.15
Continuing operations, diluted (in dollars per share)	0.33	−0.56	−1.54	−1.7	−0.11
Discontinued operations, diluted (in dollars per share)	0	0	−0.95	−0.89	−0.04
Diluted income (loss) per Class A common stock (in dollars per share)	0.33	−0.56	−2.49	−2.59	−0.15
Basic (in shares)	67	65	63	61	45
Diluted (in shares)	69	65	63	61	45

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	51	42	37	30	44
Accounts receivable, net	128	127	123	136	125
Inventory	82	92	91	85	62
Prepaid and other current assets	11	14	17	19	27
Total current assets	273	276	268	273	263
Property and equipment, net	22	27	37	27	23
Goodwill	7	7	7	7	148
Intangible assets, net	368	405	482	640	695
Operating lease assets	5	7	13	17	17
Deferred tax assets	6	5	0	—	—
Investment and other assets	2	2	3	3	29
Total assets	684	728	811	1,373	1,226
Accounts payable	11	24	23	37	17
Accrued liabilities	130	136	120	112	131
Current portion of long-term debt	15	27	28	33	18
Current portion of contingent consideration	0	20	0	—	—
Other current liabilities	4	4	5	4	4
Total current liabilities	160	210	175	304	181
Long-term debt, less current portion	279	308	367	385	340
Deferred income tax liabilities	433,000	564,000	1	2	60
Other long-term liabilities	15	23	28	23	22
Total liabilities	455	542	590	960	618
Commitments and Contingencies (Note 12)	—	—	—	—	—
Additional paid-in capital	521	508	494	491	473
Accumulated deficit	−335	−358	−322	−165	−7
Accumulated other comprehensive loss	−2	−3	794,000	−110,000	179,000
Total stockholders equity attributable to Bioventus Inc.	184	148	174	325	459
Noncontrolling interest	44	38	48	87	141
Total stockholders equity	228	186	221	412	608
Total liabilities and stockholders equity	684	728	811	1,373	1,226

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	47	50	57	55	35
Provision (benefit) for expected credit losses	1	−434,000	−1	5	485,000
Equity-based compensation	13	13	3	18	20
Impairments of assets	0	36	79	135	7
Deferred income taxes	−909,000	−5	−2	−47	−10
Unrealized (gain) loss on foreign currency fluctuations	−360,000	−259,000	665,000	1	472,000
Other, net	1	3	2	388,000	588,000
Accounts receivable	−916,000	−11	10	−18	−20
Inventory	9	−16	−6	−19	3
Accounts payable and accrued expenses	−20	18	−5	−3	18
Other current and noncurrent assets and liabilities	−2	−3	−2	10	−16
Net cash from operating activities - continuing operations	75	39	18	−11	23
Net cash from operating activities - discontinued operations	0	0	−2	−2	0
Net cash from operating activities	75	39	15	−14	23
(Settlement) proceeds from the sale of a business	−686,000	25	35	—	—
Purchase of property and equipment	−3	−1	−7	−1	−14
Investments and acquisition of distribution rights	0	−709,000	0	−10	−7
Net cash from investing activities - continuing operations	−3	23	27	−12	−284
Net cash from investing activities - discontinued operations	0	0	−12	−105	0
Net cash from investing activities	−3	23	16	−116	−284
Proceeds from issuance of Class A and B common stock	2	2	778,000	6	2
Tax withholdings on equity-based compensation	−9,000	0	0	−3	0
Receipt of deferred consideration	0	5	0	0	—
Payment of contingent consideration	−20	0	0	—	—
Borrowing on revolver	45	0	64	25	20
Payment on revolver	−45	−15	−49	−25	−20
Proceeds from the issuance of long-term debt, net of discount	32	0	0	80	257
Payments on the extinguishment of long-term debt	−66	0	0	—	—
Debt financing costs	−697,000	−1	−4	0	0
Payments on long-term debt	−9	−45	−38	−20	−91
Other, net	−827,000	−758,000	−506,000	−15,000	−404,000
Net cash from financing activities	−62	−55	−27	62	273
Effect of exchange rate changes on cash	371,000	−3	629,000	521,000	−228,000
Net change in cash and cash equivalents	10	5	5	−67	12
Accrued liabilities for distribution rights and member distributions	0	0	709,000	0	3
Accounts payable for purchase of property, plant and equipment	240,000	42,000	1	419,000	695,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro